U.S. Influenza Vaccines Market

Influenza is commonly referred as flu, a contagious respiratory illness which is caused by influenza virus. The virus can cause mild to severe illness, resulting in serious outcomes such as hospitalization or death. Geriatric population, pregnant women, and people with chronic health conditions are at high risk of serious flu complications. Influenza virus is responsible for seasonal epidemic events and are classified into two types of influenza virus, including A and B. Seasonal influenza is characterized by a sudden onset of fever, cough, headache, muscle and joint pain, sore throat and a runny nose. The cough can be severe and can last 2 or more weeks. Vaccination for influenza aids in prevention of flu. This vaccine is recommended for children aged 6 months and older. Influenza virus is transmitted primarily by respiratory secretions or droplets of the infected person. Influenza (influenza A and influenza B) epidemics occur seasonally and vary in severity each year by causing respiratory illnesses and placing a substantial burden on healthcare systems. Market Dynamics Increasing research and development of influenza vaccines by key market players is expected to drive the U.S. influenza vaccines market over the forecast period. For instance, in June 2022, Moderna, Inc., a biotechnology company, announced that they had started patient dosing in phase 3 study of seasonal influenza vaccine candidate, MRNA-1010 which is the first of several influenza vaccine candidates developed for improving traditional vaccines by inducing broad and robust immune responses. MRNA-1010 is a vaccine candidate that encodes for hemagglutinin glycoproteins for the four influenza strains for the prevention of influenza, including influenza A/H1N1, A/H3N2, and influenza B/Yamagata- and B/Victoria-lineages. Key features of the study • This report provides an in-depth analysis of the U.S. influenza vaccines market, and provides market size (USD Million) and compound annual growth rate (CAGR%) for the forecast period (2022–2030), considering 2021 as the base year • It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market • This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players • It profiles key players in the U.S. influenza vaccines market based on the following parameters – company highlights, products portfolio, key highlights, financial performance, and strategies • Key companies covered as a part of this study include Seqirus USA Inc., GSK plc., Sanofi, Pfizer Inc., AstraZeneca, Novartis AG, Merck & Co., Inc., Protein Sciences Corporation, Moderna, Inc., INOVIO Pharmaceuticals, Novavax and EMERGENT • Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics • The U.S. influenza vaccines market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts • Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the U.S. influenza vaccines market Market Segmentation • Vaccine Type Insights (Revenue, USD Bn, 2026 - 2033) o Trivalent Vaccines o Quadrivalent Vaccines • Virus Type Insights (Revenue, USD Bn, 2026 - 2033) o Influenza Virus Type A o Influenza Virus Type B • Age Group Insights (Revenue, USD Bn, 2026 - 2033) o Pediatrics o Adults • Key Players Insights o Seqirus USA Inc. o GSK plc. o Sanofi o Pfizer Inc. o AstraZeneca o Novartis AG o Merck & Co., Inc. o Protein Sciences Corporation o Moderna, Inc. o INOVIO Pharmaceuticals o Novavax o EMERGENT